| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/10/2002 | WO2001034124A3 Use of 5ht-1a-serotonine receptor agonists for treating genetic or functional rhythm disorders in the respiratory system |
| 05/10/2002 | WO2001034117A9 A method for chemoprevention of prostate cancer |
| 05/10/2002 | WO2001032155A3 Use of egfr tyrosine kinase inhibitors for treating breast cancer |
| 05/10/2002 | WO2001031007A9 Nucleic acid molecules derived from rat brain and programmed cell death models |
| 05/10/2002 | WO2001030332A3 Methods of protecting neuronal function |
| 05/10/2002 | WO2001029036A3 Allosteric sites on muscarinic receptors |
| 05/10/2002 | WO2001028580A3 Modulation of angiogenesis |
| 05/10/2002 | WO2001028545A3 Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis |
| 05/10/2002 | WO2001027146A9 Chemokine receptor |
| 05/10/2002 | WO2001026642A3 Methods and compositions for treating neurobehavioral disorders |
| 05/10/2002 | WO2001025271A3 Fibroblast growth factor-5 (fgf-5) is a tumor associated t-cell antigen |
| 05/10/2002 | WO2001024827A3 INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND αVβ3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY |
| 05/10/2002 | WO2001024784A3 New use |
| 05/10/2002 | WO2001005388A3 Use of a fatty derivative for the treatment of external secretiondisorders |
| 05/10/2002 | WO2000073507A3 Identification of a novel retrovirus associated with primary biliary cirrhosis and autoimmune disorders |
| 05/10/2002 | WO2000067736A3 Therapeutic use of an inhibitor or an antagonist of an abc protein in bone |
| 05/10/2002 | WO2000050639A3 Gene sequence variations with utility in determining the treatment of disease |
| 05/10/2002 | CA2439382A1 Pharmaceutical or dietary composition containing a vegetable oil, in particular olive oil, and sitosterol |
| 05/10/2002 | CA2431641A1 Treatment of motor fluctuations |
| 05/10/2002 | CA2427731A1 Gnrh analogues for treatment of urinary incontinence |
| 05/10/2002 | CA2427629A1 Gene regulation therapy involving ferritin |
| 05/10/2002 | CA2427572A1 Immunomodulatory peptides derived from heat shock proteins and uses thereof |
| 05/10/2002 | CA2427568A1 Tricyclic derivatives of indole with antiangiogenic activity |
| 05/10/2002 | CA2427565A1 Bis-heterocyclic compounds with antitumour and chemosensitising activity |
| 05/10/2002 | CA2427557A1 Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular diseases |
| 05/10/2002 | CA2427518A1 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 05/10/2002 | CA2427267A1 Membrane fractions of 1,2-sn-diacylglycerol-enriched cells |
| 05/10/2002 | CA2427194A1 Method for short-term and long-term drug dosimetry |
| 05/10/2002 | CA2426894A1 Method of treating and preventing migraine headaches |
| 05/10/2002 | CA2426762A1 Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors |
| 05/10/2002 | CA2426658A1 Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries |
| 05/10/2002 | CA2426284A1 Anti-adiposis composition based on garlic bulb extracts |
| 05/10/2002 | CA2425842A1 Use of il-1 inhibitors and tnf antagonists, partially in combination with recombinant erythropoietins, for the treatment of anemia |
| 05/10/2002 | CA2425583A1 Methods for obtaining inhibitors of tirc7 ligand binding and uses thereof |
| 05/10/2002 | CA2424932A1 Cd36 as a heat shock protein receptor and uses thereof |
| 05/09/2002 | WO2002036591A2 Inhalative solution formulation containing a tiotropium salt |
| 05/09/2002 | US20020056146 Expression vector for use in generation of trangenic animals; for use in animal modeling of disease |
| 05/09/2002 | US20020055667 Absorbable brachytherapy and chemotherapy delivery devices and methods |
| 05/09/2002 | US20020055666 Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors |
| 05/09/2002 | US20020055573 Stabilized monomer adhesive compositions |
| 05/09/2002 | US20020055537 Treating a crop infected with a phytopathogenic animal pest; treatment of vertebrates and humans infested by helminths or ectoparasites. |
| 05/09/2002 | US20020055533 N-(1-octyl-5-carboxymethyl-4, 6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or a pharmacologically acceptable salt thereof, and an HMG-COA reductase inhibitor; prevention or treatment of atherosclerosis or xanthoma |
| 05/09/2002 | US20020055531 Methods for treatment of inflammatory diseases |
| 05/09/2002 | US20020055529 Method for treating alzheimer's disease |
| 05/09/2002 | US20020055515 Contacting stimulated cells with a candidate compound which is an inhibitor of ATP binding to a P2Y- purinoceptor; and assaying said cells for release of one or more mediators. |
| 05/09/2002 | US20020055494 Combinations of formoterol and mometasone furoate for asthma |
| 05/09/2002 | US20020055486 Pharmaceutical composition for ophthalmic use |
| 05/09/2002 | US20020055476 RAMPs are small proteins that transport calcitonin-receptor-like proteins to the plasma membrane; drug screening |
| 05/09/2002 | US20020055462 Use |
| 05/09/2002 | US20020055460 Adminstering a compound that binds to a receptor for the glucagon-like peptide-1 (GLP-1) |
| 05/09/2002 | US20020055457 Methods of treating cancer and the pain associated therewith using endothelin antagonists |
| 05/09/2002 | US20020055163 Amino acid sequences of peptides that are encoded by genes within the human genome, the protease peptides; useful in the development of human therapeutics and diagnostic formulations |
| 05/09/2002 | US20020055160 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 05/09/2002 | US20020055122 Administering to the recipient mammal for promoting acceptance of graft, an inhibitor of the CD40/ ligand- CD40 costimulatory interaction; introducing into the recipient mammal, hematopoietic stem cells and implanting the graft |
| 05/09/2002 | US20020055092 Administering a contrast agent to a viable sample, acquiring a test data set and comparing to a comparison data set to assess the response |
| 05/09/2002 | US20020054922 Cosmetic composition and method |
| 05/09/2002 | US20020054918 Pharmaceutical compositions and methods for managing skin conditions |
| 05/09/2002 | US20020054915 Prolonged anesthesia in joints and body spaces |
| 05/09/2002 | US20020054899 Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders |
| 05/09/2002 | US20020054896 Applying onto healed wound a composition comprising a fluid, film-forming carrier, and subsequently hardening the carrier into a tangible membrane juxtaposed to the healed wound thereby reducing scarring or improving the appearance thereof |
| 05/09/2002 | US20020054881 Variants can be used in specific immunotherapy of allergic pathologies caused by dust mites |
| 05/09/2002 | US20020054876 Treatment of Alzheimer's disease |
| 05/09/2002 | US20020054870 A peptide containing atleast 6 amino acid residues, having 70% homology with part or all of the sequence containing specific 14 amino acids |
| 05/08/2002 | EP1203958A2 High-throughput screening method |
| 05/08/2002 | EP1203827A2 Polymorphisms in the human KDR gene |
| 05/08/2002 | EP1203584A1 Cholinergic precursor (in particular choline alfoscerate) associated with an acetylcholinesterase inhibitor (such as rivastigmine, donepezil) |
| 05/08/2002 | EP1203581A2 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 05/08/2002 | EP1203233A1 Method for identifying modulating compounds of neurotransmitters |
| 05/08/2002 | EP1203101A1 Ppar delta links apc to chemopreventive drugs |
| 05/08/2002 | EP1203081A2 Human intracellular signaling molecules |
| 05/08/2002 | EP1203072A2 Personal care articles |
| 05/08/2002 | EP1203025A2 NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND $g(b)1 INTEGRINS |
| 05/08/2002 | EP1203024A1 Human tumor necrosis factor receptors tr13 and tr14 |
| 05/08/2002 | EP1203023A1 Pgpcr-3 polypeptides and dna sequences thereof |
| 05/08/2002 | EP1203020A1 Modulation of human sodium channels in dorsal root ganglia |
| 05/08/2002 | EP1203016A2 Proteases and protease inhibitors |
| 05/08/2002 | EP1203015A2 Human chaperone proteins |
| 05/08/2002 | EP1202970A1 Cyclic amine derivatives for the treatment of neurological diseases |
| 05/08/2002 | EP1202959A1 Aminobenzophenones as inhibitors of il-1-beta and tnf-alpha |
| 05/08/2002 | EP1202957A1 Aminobenzophenones as inhibitors of il-1beta and tnf-alpha |
| 05/08/2002 | EP1202954A1 Novel aminobenzophenones |
| 05/08/2002 | EP1202749A2 Enzyme catalyzed anti-infective therapeutic agents |
| 05/08/2002 | EP1202746A1 Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer |
| 05/08/2002 | EP1202741A1 Neurotropic virus transport |
| 05/08/2002 | EP1202737A2 Antiviral therapy use of p-glycoprotein modulators |
| 05/08/2002 | EP1202736A1 Nicotine in therapeutic angiogenesis and vasculogenesis |
| 05/08/2002 | EP1202733A1 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 05/08/2002 | EP1202730A2 Use of ep4 receptor ligands in the treatment of neuropathic pain and colon cancer |
| 05/08/2002 | EP1202727A1 Use of agonists of gabab receptors and pharmaceutically acceptable derivatives thereof, in the therapy of maintaining nicotine abstinence in nicotine-dependent patients |
| 05/08/2002 | EP1202723A2 Use of anti-muscarinic agents for treating skin disorders |
| 05/08/2002 | EP1202722A1 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 05/08/2002 | EP1202721A1 Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof |
| 05/08/2002 | EP1202717A2 Naaladase inhibitors in anxiety and memory disorders |
| 05/08/2002 | EP1202626A1 Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof |
| 05/08/2002 | EP1202620A1 Anti-inflammatory therapy for inflammatory mediated infection |
| 05/08/2002 | EP1024823B1 Prevention and treatment of adhesion formation |
| 05/08/2002 | EP0839052B1 Use of hyaluronic acid and a nsaid for the manufacture of a medicament for the treatment of mucosal diseases |
| 05/08/2002 | EP0708653B1 Assay and reagents for identifying anti-proliferative agents |
| 05/08/2002 | DE10152369A1 Stable, propellant-free inhalable liquid medicament for treating asthma or chronic obstructive pulmonary disease, containing tiotropium salt and antiallergic agent, antihistamine, steroid or leukotriene antagonist |
| 05/08/2002 | DE10054278A1 Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Osteoporose Use of stimulators of soluble guanylate cyclase for the treatment of osteoporosis |